Gilead and Sangamo deal shows that CRISPR still has competition – Chemical & Engineering News
Chemical & Engineering News |
Gilead and Sangamo deal shows that CRISPR still has competition
Chemical & Engineering News Sangamo says that making and testing its zinc finger nuclease (ZFN) gene-editing technology, once an arduous process, has been greatly accelerated thanks to this robot and a large library of ZFNs that can be quickly linked together and tested in cells … Sangamo in $3 billion gene-editing deal with Gilead East Bay gene editing company snags Gilead deal worth up to $3.2 billion Gilead, Sangamo strike $3B off-the-shelf CAR-T deal |
